GASTROINTESTINAL STROMAL TUMORS
Clinical trials for GASTROINTESTINAL STROMAL TUMORS explained in plain language.
Never miss a new study
Get alerted when new GASTROINTESTINAL STROMAL TUMORS trials appear
Sign up with your email to follow new studies for GASTROINTESTINAL STROMAL TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for GIST patients: ripretinib takes on sunitinib in major trial
Disease control OngoingThis phase 3 trial compares two targeted cancer pills, ripretinib and sunitinib, in about 450 people with advanced gastrointestinal stromal tumor (GIST) whose first treatment (imatinib) stopped working or caused side effects. The main goal is to see if ripretinib delays cancer gr…
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New hope for rare GIST mutations: regorafenib trial targets stubborn tumors
Disease control OngoingThis study tests whether the drug regorafenib can help control gastrointestinal stromal tumors (GIST) that have specific gene changes (KIT exon 17, 18, or 14, or SDHB deficiency) after imatinib stops working. It includes adults with measurable, unresectable tumors. The main goal …
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo targets Hard-to-Treat stomach tumors
Disease control OngoingThis early-phase trial tests a new drug, pimitespib (TAS-116), combined with the standard drug imatinib in people with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to imatinib. The study aims to find the safest dose, check for side effects, and see…
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for drug-resistant GIST: combo therapy targets stubborn tumors
Disease control OngoingThis study tests a new two-drug combination (bezuclastinib plus sunitinib) in 40 adults with advanced gastrointestinal stromal tumors (GIST) that grew while on sunitinib alone. The goal is to see if the combo can slow cancer progression and understand why some tumors resist treat…
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE2 • Sponsor: Sarcoma Alliance for Research through Collaboration • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC